FDA Taps Szarama as Acting CBER Director as Prasad’s Tumultuous Tenure Ends

Why It Matters

Leadership continuity at CBER is critical for timely review of vaccines and biologics, and Szarama’s appointment aims to stabilize the division after a period of controversy that rattled biotech firms.

Key Takeaways

• Szarama, a biophysicist, becomes acting CBER director after Prasad's exit
• Prasad's tenure marked by rare‑disease therapy rejections and Elevidys controversy
• Acting appointments signal leadership instability across HHS agencies in 2025‑26
• Szarama's background includes CMS research and ARPA‑H program management
• FDA Commissioner Makary says CBER selection process is progressing

Pulse Analysis

Vinay Prasad’s departure from the FDA’s Center for Biologics Evaluation and Research (CBER) closes a turbulent chapter that has reverberated through the biotech sector. During his two‑year stint, Prasad oversaw the high‑profile rejection of several rare‑disease therapies and the temporary halt of Sarepta Therapeutics’ Elevidys gene‑therapy after two teenage deaths. Critics argued his data‑driven approach slowed access to life‑saving treatments, while industry groups warned of heightened uncertainty for pipeline developers. The episode highlighted the delicate balance regulators must strike between safety rigor and market predictability.

Katherine Szarama, a Johns Hopkins‑trained biophysicist, steps in as acting CBER director, bringing a blend of scientific expertise and federal program management. Her résumé includes stints at the Centers for Medicare and Medicaid Services and as a program manager for ARPA‑H, where she oversaw innovative health‑technology initiatives. Observers expect Szarama to adopt a more collaborative stance with manufacturers, leveraging her research background to streamline review timelines without compromising safety. Her appointment also signals the FDA’s intent to restore confidence among rare‑disease developers after the turbulence of Prasad’s rule.

The acting‑director pattern is not confined to CBER; recent months have seen temporary heads at CDER, the CDC and other HHS entities, underscoring a broader leadership churn. Such instability can delay policy implementation, affect funding allocations, and create strategic ambiguity for companies planning clinical trials or product launches. By stabilizing CBER under Szarama while a permanent nominee is vetted, the FDA aims to reassure investors and patients that the biologics pipeline will remain on track. Consistent oversight is essential for maintaining the United States’ position as a global hub for vaccine and biologic innovation.